Neurological complications of systemic cancer

The Lancet Neurology

Volumn 9, Issue 12, 2010, Pages 1214-1227

  Khasraw, Mustafa ^a   Posner, Jerome B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CEPHALOSPORIN DERIVATIVE; CORTICOSTEROID; CYCLOSPORIN; CYTARABINE; FLUOROURACIL; IFOSFAMIDE; INTERFERON; METHOTREXATE; PACLITAXEL; SEROTONIN UPTAKE INHIBITOR; SUNITINIB; TACROLIMUS;

BRAIN; BRAIN DISEASE; BRAIN METASTASIS; BREAST CANCER; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DEMENTIA; DIAGNOSTIC ACCURACY; DISABILITY; DISTRESS SYNDROME; DRUG MEGADOSE; EARLY DIAGNOSIS; FATALITY; HUMAN; LABORATORY TEST; LUNG CANCER; MENINGEAL METASTASIS; NEOPLASM; NEUROLOGICAL COMPLICATION; PARANEOPLASTIC SYNDROME; PERIPHERAL NERVE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; QUALITY OF LIFE; REVIEW; SOMNOLENCE; SPINAL CORD; SPINAL CORD DISEASE; SYMPTOM; SYSTEMIC DISEASE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

BRAIN DISEASES; COGNITION DISORDERS; HUMANS; NEOPLASMS; NERVOUS SYSTEM DISEASES; SPINAL CORD DISEASES;

EID: 78349263026     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70220-9     Document Type: Review

References (131)

1. Pruitt AA Central nervous system infections in cancer patients. Semin Neurol 2004, 24:435-452.
2. Schiff D, Wen PY, van den Bent MJ Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol 2009, 6:596-603.
3. Kaley TJ, Deangelis LM Therapy of chemotherapy-induced peripheral neuropathy. Br J Haematol 2009, 145:3-14.
4. Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY CNS complications of radiotherapy and chemotherapy. Lancet 2009, 374:1639-1651.
5. Bush SH, Bruera E The assessment and management of delirium in cancer patients. Oncologist 2009, 14:1039-1049.
6. Nguyen T, DeAngelis LM Stroke in cancer patients. Curr Neurol Neurosci Rep 2006, 6:187-192.
7. Kuo SH, Debnam JM, Fuller GN, de Groot J Wernicke's encephalopathy: an underrecognized and reversible cause of confusional state in cancer patients. Oncology 2009, 76:10-18.
8. Darnell RB, Posner JB Paraneoplastic syndromes affecting the nervous system. Semin Oncol 2006, 33:270-298.
9. Steeg PS Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
10. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
11. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993, 33:583-590.
12. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470-1476.
13. Rades D, Kueter JD, Pluemer A, Veninga T, Schild SE A matched-pair analysis comparing whole-brain radiotherapy plus stereotactic radiosurgery versus surgery plus whole-brain radiotherapy and a boost to the metastatic site for one or two brain metastases. Int J Radiat Oncol Biol Phys 2009, 73:1077-1081.
14. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
15. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
16. Lutterbach J, Bartelt S, Ostertag C Long-term survival in patients with brain metastases. J Cancer Res Clin Oncol 2002, 128:417-425.
17. Palmieri D, Smith QR, Lockman PR, et al. Brain metastases of breast cancer. Breast Dis 2006, 26:139-147.
18. Cole JS, Patchell RA Metastatic epidural spinal cord compression. Lancet Neurol 2008, 7:459-466.
19. Chamberlain MC, Glantz M, Groves MD, Wilson WH Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment. Semin Oncol 2009, 36(suppl 2):S35-S45.
20. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH Neurolymphomatosis. Neuro Oncol 2003, 5:104-115.
21. Pearson CM Incidence and type of pathologic alterations observed in muscle in a routine autopsy survey. Neurology 1959, 9:757-766.
22. Tuma R, DeAngelis LM Altered mental status in patients with cancer. Arch Neurol 2000, 57:1727-1731.
23. Doriath V, Paesmans M, Catteau G, Hildebrand J Acute confusion in patients with systemic cancer. J Neurooncol 2007, 83:285-289.
24. Meagher DJ, O'Hanlon D, O'Mahony E, Casey PR, Trzepacz PT Relationship between symptoms and motoric subtype of delirium. J Neuropsychiatry Clin Neurosci 2000, 12:51-56.
25. Inouye SK, Foreman MD, Mion LC, Katz KH, Cooney LM Nurses' recognition of delirium and its symptoms: comparison of nurse and researcher ratings. Arch Intern Med 2001, 161:2467-2473.
26. Gagnon B, Low G, Schreier G Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 2005, 30:100-107.
27. Oberndorfer S, Schmal T, Lahrmann H, Urbanits S, Lindner K, Grisold W The frequency of seizures in patients with primary brain tumors or cerebral metastases: an evaluation from the Ludwig Boltzmann Institute of NeuroOncology and the Department of Neurology, Kaiser Franz Josef Hospital, Vienna. Wien Klin Wochenschr 2002, 114:911-916.
28. Avila EK, Graber J Seizures and epilepsy in cancer patients. Curr Neurol Neurosci Rep 2010, 10:60-67.
29. Glantz MJ, Cole BF, Forsyth PA, et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
30. Mamon HJ, Wen PY, Burns AC, Loeffler JS Allergic skin reactions to anticonvulsant medications in patients receiving cranial radiation therapy. Epilepsia 1999, 40:341-344.
31. Drislane FW Nonconvulsive status epilepticus in patients with cancer. Clin Neurol Neurosurg 1994, 96:314-318.
32. Towne AR, Waterhouse EJ, Boggs JG, et al. Prevalence of nonconvulsive status epilepticus in comatose patients. Neurology 2000, 54:340-345.
33. Husain AM, Horn GJ, Jacobson MP Non-convulsive status epilepticus: usefulness of clinical features in selecting patients for urgent EEG. J Neurol Neurosurg Psychiatry 2003, 74:189-191.
34. Primavera A, Audenino D, Cocito L Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci 2002, 29:180-183.
35. Martinez-Rodriguez JE, Barriga FJ, Santamaria J, et al. Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure. Am J Med 2001, 111:115-119.
36. Hotchkiss RS, Karl IE The pathophysiology and treatment of sepsis. N Engl J Med 2003, 348:138-150.
37. Pytel P, Alexander JJ Pathogenesis of septic encephalopathy. Curr Opin Neurol 2009, 22:283-287.
38. Madow L, Alpers BJ Encephalitic form of metastatic carcinoma. AMA Arch Neurol Psychiatry 1951, 65:161-173.
39. Posner JB, Saper CB, Schiff N, Plum F Plum and Posner's diagnosis of stupor and coma 2007, Oxford University Press, New York.
40. Winawer N Postoperative delirium. Med Clin North Am 2001, 85:1229-1239.
41. Lansford CD, Guerriero CH, Kocan MJ, et al. Improved outcomes in patients with head and neck cancer using a standardized care protocol for postoperative alcohol withdrawal. Arch Otolaryngol Head Neck Surg 2008, 134:865-872.
42. Kumar CN, Andrade C, Murthy P A randomized, double-blind comparison of lorazepam and chlordiazepoxide in patients with uncomplicated alcohol withdrawal. J Stud Alcohol Drugs 2009, 70:467-474.
43. DeAngelis L, Posner J Neurologic complication of cancer 2009, Oxford University Press, New York. 2nd edn.
44. Ajithkumar T, Parkinson C, Shamshad F, Murray P Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol) 2007, 19:108-114.
45. Sweiss KI, Beri R, Shord SS Encephalopathy after high-dose ifosfamide: a retrospective cohort study and review of the literature. Drug Saf 2008, 31:989-996.
46. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Pastorelli D Important role of thiamine in preventing ifosfamide-induced encephalopathy. J Oncol Pharm Pract 2009, 12:237-239.
47. Inaba H, Khan RB, Laningham FH, Crews KR, Pui CH, Daw NC Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol 2008, 19:178-184.
48. Linnebank M, Malessa S, Moskau S, et al. Acute methotrexate-induced encephalopathy-causal relation to homozygous allelic state for MTR c2756A>G (D919G)?. J Chemother 2007, 19:455-457.
49. Muller J, Kralovanszky J, Adleff V, et al. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism. Anticancer Res 2008, 28:3051-3054.
50. Vaughn C, Zhang L, Schiff D Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 2008, 10:86-91.
51. Young DF, Posner JB, Chu F, Nisce L Rapid-course radiation therapy of cerebral metastases: results and complications. Cancer 1974, 34:1069-1076.
52. Aznar AO, Montero MA, Rovira R, Vidal FR Intravascular large B-cell lymphoma presenting with neurological syndromes: clinicopathologic study. Clin Neuropathol 2007, 26:180-186.
53. Menke MN, Feke GT, McMeel JW, Treon SP Ophthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009, 9:100-103.
54. Collins RC, Al-Mondhiry H, Chernik NL, Posner JB Neurologic manifestations of intravascular coagulation in patients with cancer: a clinicopathologic analysis of 12 cases. Neurology 1975, 25:795-806.
55. Shimada K, Kinoshita T, Naoe T, Nakamura S Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol 2009, 10:895-902.
56. Tuzun E, Dalmau J Limbic encephalitis and variants: classification, diagnosis and treatment. Neurologist 2007, 13:261-271.
57. McKeon A, Apiwattanakul M, Lachance DH, et al. Positron emission tomography-computed tomography in paraneoplastic neurologic disorders: systematic analysis and review. Arch Neurol 2010, 67:322-329.
58. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098.
59. Chang G, Meadows ME, Orav EJ, Antin JH Mental status changes after hematopoietic stem cell transplantation. Cancer 2009, 115:4625-4635.
60. Vardy J, Rourke S, Tannock IF Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007, 25:2455-2463.
61. Vardy JL, Xu W, Booth CM, et al. Relation between perceived cognitive function and neuropsychological performance in survivors of breast and colorectal cancer. J Clin Oncol (Meeting Abstracts) 2008, 26(suppl 15):9520.
62. Hermelink K, Kuchenhoff H, Untch M, et al. Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 2010, published online Feb 2. 10.1002/pon.1695.
63. Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007, 103:303-311.
64. Poppelreuter M, Weis J, Bartsch HH Effects of specific neuropsychological training programs for breast cancer patients after adjuvant chemotherapy. J Psychosoc Oncol 2009, 27:274-296.
65. Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, et al. The effect of modafinil on cognitive function in breast cancer survivors. Cancer 2009, 115:2605-2616.
66. Snyderman D, Wynn D Depression in cancer patients. Prim Care 2009, 36:703-719.
67. Hardy SE Methylphenidate for the treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. Am J Geriatr Pharmacother 2009, 7:34-59.
68. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR Cancer-related fatigue: the scale of the problem. Oncologist 2007, 12(suppl 1):4-10.
69. Pelletier G, Verhoef MJ, Khatri N, Hagen N Quality of life in brain tumor patients: the relative contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol 2002, 57:41-49.
70. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR Pharmacologic treatment of cancer-related fatigue. Oncologist 2007, 12(suppl 1):43-51.
71. Mustian KM, Morrow GR, Carroll JK, Figueroa-Moseley CD, Jean-Pierre P, Williams GC Integrative nonpharmacologic behavioral interventions for the management of cancer-related fatigue. Oncologist 2007, 12(suppl 1):52-67.
72. Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, et al. Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. Int J Radiat Oncol Biol Phys 2008, 72:19-23.
73. Gavrilovic IT, Posner JB Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5-14.
74. Smedby KE, Brandt L, Backlund ML, Blomqvist P Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009, 101:1919-1924.
75. Steeg PS Brain metastasis: a unique microenvironment and a sanctuary from chemotherapy. American Association for Cancer Research 101st Annual Meeting Education Book 2008, 91-93. AACR, Philadelphia.
76. Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS The biology of metastasis to a sanctuary site. Clin Cancer Res 2007, 13:1656-1662.
77. Duchnowska R, Dziadziuszko R, Czartoryska-Arlukowicz B, et al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res Treat 2009, 117:297-303.
78. Slimane K, Andre F, Delaloge S, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004, 15:1640-1644.
79. Niwinska A, Murawska M, Pogoda K Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 2009, 21:942-948.
80. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol 2008, 19:1561-1565.
81. Drlicek M, Bodenteich A, Urbanits S, Grisold W Immunohistochemical panel of antibodies in the diagnosis of brain metastases of the unknown primary. Pathol Res Pract 2004, 200:727-734.
82. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483-2491.
83. Mueller RP, Soffietti R, Abaciouglu MU, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (Meeting Abstracts) 2009, 27:2008.
84. McPherson CM, Suki D, Feiz-Erfan I, et al. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro Oncol 2010, published online Feb 14. 10.1093/neuonc/noq005.
85. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
86. Viani GA, Manta GB, Fonseca EC, De Fendi LI, Afonso SL, Stefano EJ Whole brain radiotherapy with radiosensitizer for brain metastases. J Exp Clin Cancer Res 2009, 28:1.
87. Mehta MP, Shapiro WR, Phan SC, et al. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 2009, 73:1069-1076.
88. Blanchard P, Le Péchoux C Prophylactic cranial irradiation in lung cancer. Curr Opin Oncol 2010, 22:94-101.
89. Pottgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol 2007, 25:4987-4992.
90. Movsas B, Bae K, Meyers C, et al. Phase III study of prophylactic cranial irradiation vs observation in patients with stage III non-small-cell lung cancer: neurocognitive and quality of life analysis of RTOG 0214. Int J Radia Oncol Biol Phys 2009, 75:S1.
91. Dawood S, Gonzalez-Angulo AM, Albarracin C, et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy. Cancer 2010, 116:3084-3092.
92. van der Ree TC, Dippel DW, Avezaat CJ, Smitt PA Sillevis, Vecht CJ, van den Bent MJ Leptomeningeal metastasis after surgical resection of brain metastases. J Neurol Neurosurg Psychiatry 1999, 66:225-227.
93. Chamberlain MC Leptomeningeal metastasis. Curr Opin Neurol 2009, 22:665-674.
94. Wasserstrom WR, Glass JP, Posner JB Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49:759-772.
95. O'Meara WP, Borkar SA, Stambuk HE, Lymberis SC Leptomeningeal metastasis. Curr Probl Cancer 2007, 31:367-424.
96. Tha KK, Terae S, Kudo K, Miyasaka K Differential diagnosis of hyperintense cerebrospinal fluid on fluid-attenuated inversion recovery images of the brain-part I: pathological conditions. Br J Radiol 2009, 82:426-434.
97. Tha KK, Terae S, Kudo K, Miyasaka K Differential diagnosis of hyperintense cerebrospinal fluid on fluid-attenuated inversion recovery images of the brain-part II: non-pathological conditions. Br J Radiol 2009, 82:610-614.
98. Omuro AM, Lallana EC, Bilsky MH, DeAngelis LM Ventriculoperitoneal shunt in patients with leptomeningeal metastasis. Neurology 2005, 64:1625-1627.
99. Zeiser R, Burger JA, Bley TA, Windfuhr-Blum M, Schulte-Monting J, Behringer DM Clinical follow-up indicates differential accuracy of magnetic resonance imaging and immunocytology of the cerebral spinal fluid for the diagnosis of neoplastic meningitis-a single centre experience. Br J Haematol 2004, 124:762-768.
100. Ferrario C, Davidson A, Bouganim N, Aloyz R, Panasci LC Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann Oncol 2009, 20:792-795.
101. Jaime-Perez JC, Rodriguez-Romo LN, Gonzalez-Llano O, Chapa-Rodriguez A, Gomez-Almaguer D Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy. Br J Haematol 2009, 144:794-795.
102. Glantz MJ, Van Horn A, Fisher R, Chamberlain MC Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer 2010, 116:1947-1952.
103. Clarke JL, Perez HR, Jacks LM, Panageas KS, DeAngelis LM Leptomeningeal metastases in the MRI era. Neurology 2010, 74:1449-1454.
104. Navi BB, Reichman JS, Berlin D, et al. Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology 2010, 74:494-501.
105. Rogers LR Cerebrovascular complications in cancer patients. Neurol Clin 2003, 21:167-192.
106. Cestari DM, Weine DM, Panageas KS, Segal AZ, DeAngelis LM Stroke in patients with cancer: incidence and etiology. Neurology 2004, 62:2025-2030.
107. Stefan O, Vera N, Otto B, Heinz L, Wolfgang G Stroke in cancer patients: a risk factor analysis. J Neurooncol 2009, 94:221-226.
108. Ghatak NR Pathology of cerebral embolization caused by nonthrombotic agents. Hum Pathol 1975, 6:599-610.
109. Taccone FS, Jeangette SM, Blecic SA First-ever stroke as initial presentation of systemic cancer. J Stroke Cerebrovasc Dis 2008, 17:169-174.
110. Kwon HM, Kang BS, Yoon BW Stroke as the first manifestation of concealed cancer. J Neurol Sci 2007, 258:80-83.
111. Hong CT, Tsai LK, Jeng JS Patterns of acute cerebral infarcts in patients with active malignancy using diffusion-weighted imaging. Cerebrovasc Dis 2009, 28:411-416.
112. Lee AYY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349:146-153.
113. Rogers LR Cerebrovascular complications in patients with cancer. Semin Neurol 2004, 24:453-460.
114. Poungvarin N, Bhoopat W, Viriyavejakul A, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. N Engl J Med 1987, 316:1229-1233.
115. Nimjee SM, Powers CJ, Bulsara KR Review of the literature on de novo formation of cavernous malformations of the central nervous system after radiation therapy. Neurosurg Focus 2006, 21:e4.
116. Carden CP, Larkin JM, Rosenthal MA What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol 2008, 10:624-630.
117. Besse B, Lasserre SF, Compton P, Huang J, Augustus S, Rohr UP Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 2010, 16:269-278.
118. Khasraw M, Goldlust SAABL, DeAngelis LM Retrospective review of intracranial hemorrhage (ICH) in cancer patients treated with bevacizumab; the Memorial Sloan-Kettering (MSK) experience. Neurology 2010, 74:A594. A.
119. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009, 113:4834-4840.
120. Roodman GD Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
121. Schiff D Spinal cord compression. Neurol Clin 2003, 21:67-86.
122. Schiff D, O'Neill BP, Suman VJ Spinal epidural metastasis as the initial manifestation of malignancy: clinical features and diagnostic approach. Neurology 1997, 49:452-456.
123. Gilbert RW, Kim JH, Posner JB Epidural spinal cord compression from metastatic tumor: diagnosis and treatment. Ann Neurol 1978, 3:40-51.
124. Vecht CJ, Haaxma-Reiche H, van Putten WL, de Visser M, Vries EP, Twijnstra A Initial bolus of conventional versus high-dose dexamethasone in metastatic spinal cord compression. Neurology 1989, 39:1255-1257.
125. Greenberg HS, Kim JH, Posner JB Epidural spinal cord compression from metastatic tumor: results with a new treatment protocol. Ann Neurol 1980, 8:361-366.
126. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994, 30:22-27.
127. Patchell RA, Tibbs PA, Regine WF, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005, 366:643-648.
128. Rades D, Lange M, Veninga T, et al. Preliminary results of spinal cord compression recurrence evaluation (score-1) study comparing short-course versus long-course radiotherapy for local control of malignant epidural spinal cord compression. Int J Radiat Oncol Biol Phys 2009, 73:228-234.
129. Antoine JC, Camdessanché JP Peripheral nervous system involvement in patients with cancer. Lancet Neurol 2007, 6:75-86.
130. Grothey A, Nikcevich DA, Sloan JA, et al. Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: results from a placebo-controlled phase III trial. J Clin Oncol (Meeting Abstracts) 2009, 27:4025.
131. Kinn AC, Lantz B Vitamin B12 deficiency after irradiation for bladder carcinoma. J Urol 1984, 131:888-890.